1. Home
  2. WVE vs MDXG Comparison

WVE vs MDXG Comparison

Compare WVE & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

BUY

Current Price

$3.45

Market Cap

744.8M

Sector

Health Care

ML Signal

BUY

Logo MiMedx Group Inc

MDXG

MiMedx Group Inc

SELL

Current Price

$4.60

Market Cap

672.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
WVE
MDXG
Founded
2012
2006
Country
United States
United States
Employees
N/A
808
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
744.8M
672.8M
IPO Year
2015
2007

Fundamental Metrics

Financial Performance
Metric
WVE
MDXG
Price
$3.45
$4.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
19
5
Target Price
★ $18.06
$7.40
AVG Volume (30 Days)
★ 2.9M
965.8K
Earning Date
11-09-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 14.29
EPS
N/A
★ N/A
Revenue
$3,704,000.00
★ $418,630,000.00
Revenue This Year
$19.21
N/A
Revenue Next Year
N/A
$21.78
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 149.43
19.99
52 Week Low
$3.43
$3.03
52 Week High
$21.73
$7.97

Technical Indicators

Market Signals
Indicator
WVE
MDXG
Relative Strength Index (RSI) 25.92 49.65
Support Level N/A $4.37
Resistance Level $6.33 $4.76
Average True Range (ATR) 0.23 0.16
MACD -0.02 -0.03
Stochastic Oscillator 8.56 33.90

Price Performance

Historical Comparison
WVE
MDXG

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About MDXG MiMedx Group Inc

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Share on Social Networks: